Rigel Pharmaceuticals receives milestone payments from AstraZeneca
The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) by AstraZeneca. The second milestone marks the completion
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.